Boehringer Ingelheim advances its oncology research program through innovative partnerships

Ingelheim, Germany, Tue, 11/05/2024 - 12:00

Boehringer Ingelheim in the past weeks has announced a series of partnerships adding groundbreaking approaches with the potential to take oncology research to the next level.

The advancements are part of Boehringer Ingelheim’s commitment to transforming the lives of people living with cancer through boldness, perseverance, smart risk-taking, and unwavering optimism.
The company's most recent oncology collaboration with Circle Pharma aims to develop new, first-in-class molecules that can potentially halt cancer cell growth.
The acquisition of Nerio Therapeutics aims to further advance the development of novel immuno-oncology treatments.

Why it matters

Despite significant advancements in cancer treatment, the disease continues to affect millions of people every year. Boehringer Ingelheim is committed to changing this and extending the benefits of immuno-oncology and cancer cell-directed therapies to more cancer patients.
In September Boehringer Ingelheim announced a new collaboration with Circle Pharma, aiming to develop first-in-class molecules that can potentially halt cancer cell growth. Circle specializes in drug discovery of macrocycle therapies, which are large enough to bind selectively to challenging targets involved in cancer cell growth and small enough to penetrate cancer cells.
Parallel to this, Boehringer Ingelheim recently acquired Nerio Therapeutics, adding an additional first-in-class opportunity to its pipeline. Nerio has developed a next-generation inhibitor for Protein Tyrosine Phosphatases N2 and N1 (PTPN2 and PTPN1), which act as immune checkpoints. By inhibiting these molecules, sustained immune cell activation can be achieved, allowing the immune system to fight cancer cells more effectively and potentially in sustained manner.

Detlev Mennerich, Global Head of Business Development & Licensing at Boehringer Ingelheim:

"Building on our internal strength in drug discovery, external partnerships provide significant opportunities to synergize on pioneering ideas toward clinical success. They fuel our innovation, accelerate our progress, and bring us closer to our ambition: delivering meaningful clinical advances, with the ultimate goal of curing a range of cancers."

More info:

Link to Circle Pharma press release here
Link to Nerio press release here
Link to BIO Europe, the continent's leading partnering event here

About Boehringer Ingelheim

Boehringer Ingelheim is a global leader in pharmaceutical research and development. Independent since its foundation in 1885, Boehringer Ingelheim takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at www.boehringer-ingelheim.com.

About Boehringer Ingelheim's Oncology Partnerships

Boehringer Ingelheim's oncology partnerships are part of the company's commitment to transforming the lives of people living with cancer. The company is building one of the most innovative cancer pipelines, with results beginning to show, particularly with the groundbreaking zongertinib data.

Boehringer Ingelheim’s Intended Audiences Notice

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country.